FDG-PET in Cognitive Impairment and Dementia.

Neuroimaging is crucial in early and accurate assessment of diagnosis, prognosis, and therapy optimization in patients with declining cognitive abilities. Imaging modalities now available for clinical indications related to neurodegenerative processes include Computed Tomography (CT), MR imaging, and PET imaging with 6 positron-emitting radiotracers approved at this time by the US Food and Drug Administration. The central focus of this article is the role of FDG-PET in clinical and research applications of patients with cognitive problems, and how the derived information may be effectively integrated with information acquired from other neuroimaging modalities.